StockData
Corbus Pharmaceuticals Holdings, Inc. logo

Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock

CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$3.01−0.37 (-10.81%)

Close on Nov 17, 2026Market cap $58.22MP/E –Yield –

Corbus Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Corbus Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $90.26M, up 79.0% year over year. For fiscal 2025 it was $70.10M, up 117.5% from the year before. Over ten years it grew 28.1% a year on average. The highest annual figure on record is $98.27M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$70.10M+117.5%
FY2024Dec 31, 2024$32.22M+3.4%
FY2023Dec 31, 2023$31.17M+93.1%
FY2022Dec 31, 2022$16.14M-55.7%
FY2021Dec 31, 2021$36.45M-62.9%
FY2020Dec 31, 2020$98.27M+9.7%
FY2019Dec 31, 2019$89.60M+84.3%
FY2018Dec 31, 2018$48.61M+86.7%
FY2017Dec 31, 2017$26.04M+68.7%
FY2016Dec 31, 2016$15.44M+162.1%
FY2015Dec 31, 2015$5.89M+369.0%
FY2014Dec 31, 2014$1.26M+496.0%
FY2013Dec 31, 2013$210.67K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$31.18M+105.3%
Q1 FY2026Mar 31, 2026$19.82M+26.7%
Q4 FY2025Dec 31, 2025$18.41M+109.5%
Q3 FY2025Sep 30, 2025$20.86M+93.0%
Q2 FY2025Jun 30, 2025$15.19M+121.2%
Q1 FY2025Mar 31, 2025$15.64M+171.5%
Q4 FY2024Dec 31, 2024$8.79M+25.9%
Q3 FY2024Sep 30, 2024$10.81M+65.0%
Q2 FY2024Jun 30, 2024$6.87M+61.6%
Q1 FY2024Mar 31, 2024$5.76M-57.0%
Q4 FY2023Dec 31, 2023$6.98M+11.8%
Q3 FY2023Sep 30, 2023$6.55M+59.5%
Q2 FY2023Jun 30, 2023$4.25M+70.0%
Q1 FY2023Mar 31, 2023$13.39M+307.4%
Q4 FY2022Dec 31, 2022$6.24M+1542.8%
Q3 FY2022Sep 30, 2022$4.11M-52.8%
Q2 FY2022Jun 30, 2022$2.50M-77.8%
Q1 FY2022Mar 31, 2022$3.29M-69.3%
Q4 FY2021Dec 31, 2021$380.00K-97.6%
Q3 FY2021Sep 30, 2021$8.70M-68.4%
Q2 FY2021Jun 30, 2021$11.27M-63.3%
Q1 FY2021Mar 31, 2021$10.72M-55.2%
Q4 FY2020Dec 31, 2020$16.11M-31.4%
Q3 FY2020Sep 30, 2020$27.52M+24.2%
Q2 FY2020Jun 30, 2020$30.69M+38.3%
Q1 FY2020Mar 31, 2020$23.95M+9.9%
Q4 FY2019Dec 31, 2019$23.49M+48.8%
Q3 FY2019Sep 30, 2019$22.15M+73.0%
Q2 FY2019Jun 30, 2019$22.18M+116.2%
Q1 FY2019Mar 31, 2019$21.78M+123.1%
Q4 FY2018Dec 31, 2018$15.78M+90.4%
Q3 FY2018Sep 30, 2018$12.81M+127.8%
Q2 FY2018Jun 30, 2018$10.26M+78.0%
Q1 FY2018Mar 31, 2018$9.77M+53.4%
Q4 FY2017Dec 31, 2017$8.29M+54.0%
Q3 FY2017Sep 30, 2017$5.62M+30.3%
Q2 FY2017Jun 30, 2017$5.76M–
Q1 FY2017Mar 31, 2017$6.37M–
Q4 FY2016Dec 31, 2016$5.38M–
Q3 FY2016Sep 30, 2016$4.32M–

More Corbus Pharmaceuticals figures

See a number that looks wrong?